The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 15, 2020

Filed:

Nov. 13, 2015
Applicant:

Indiana University Research and Technology Corporation, Indianapolis, IN (US);

Inventor:

John J. Turchi, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); A61P 35/00 (2006.01); C07D 403/04 (2006.01); C07D 231/06 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01); C07D 231/06 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/14 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01);
Abstract

Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibit the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.


Find Patent Forward Citations

Loading…